What is the appropriate dosing of ursodeoxycholic acid (UDCA) in adults and children?

Ursodeoxycholic Acid Dosing

The dose of ursodeoxycholic acid depends entirely on the indication: for primary biliary cholangitis (PBC), use 13-15 mg/kg/day as a single bedtime dose; for intrahepatic cholestasis of pregnancy, use 10-15 mg/kg/day divided into 2-3 doses; for gallstone dissolution, use 8-10 mg/kg/day in divided doses; and critically, avoid high-dose UDCA (28-30 mg/kg/day) in primary sclerosing cholangitis due to increased mortality risk. 1, 2

Primary Biliary Cholangitis (PBC) – First-Line Therapy

For PBC, administer UDCA at 13-15 mg/kg/day as a single bedtime dose. 1, 3 This is the established first-line treatment and should be initiated as early as possible in the disease course. 1

• This dosing regimen significantly decreases serum bilirubin, alkaline phosphatase, cholesterol, and immunoglobulin M levels compared to placebo. 1, 3
• Long-term treatment at this dose delays histological progression when started at early disease stages. 1, 3
• Treatment is associated with significant reduction in likelihood of liver transplantation or death in patients with moderate to severe PBC. 1, 3
• Biochemical response should be evaluated after 1 year of therapy to identify patients at risk of progressive disease who may need second-line agents. 1
• A dose-response study confirmed that 900 mg/day (approximately 13.5 mg/kg/day) produces optimal enrichment of UDCA in serum bile acids and the greatest improvement in liver function tests. 4
• Comparative trials demonstrate that 13-15 mg/kg/day is superior to lower doses (5-7 mg/kg/day) and equivalent to higher doses (23-25 mg/kg/day) for improving alkaline phosphatase, AST, and Mayo risk score. 5

Post-Liver Transplant PBC Management

• After liver transplantation for PBC, use UDCA 10-15 mg/kg/day in two divided doses lifelong to prevent recurrence. 1, 3
• This regimen is associated with lower risk of PBC recurrence and reduced long-term risk of graft loss, liver-related death, and all-cause death. 3

Intrahepatic Cholestasis of Pregnancy (ICP)

For ICP, start with 10-15 mg/kg/day divided into 2-3 daily doses. 1, 3

• Decrease in pruritus typically occurs within 1-2 weeks, and biochemical improvement is usually seen within 3-4 weeks. 1, 3
• If pruritus is not relieved after initial treatment, the dose can be titrated to a maximum of 21 mg/kg/day. 1, 3
• Continue treatment until delivery, as ICP typically resolves postpartum. 6
• UDCA is considered safe during pregnancy and breastfeeding, with no teratogenic effects reported. 1, 3
• When coagulation parameters (prolonged PT/INR) are abnormal, add vitamin K supplementation. 1, 6

Primary Sclerosing Cholangitis (PSC) – Critical Warnings

UDCA is NOT recommended for routine treatment of newly diagnosed PSC. 7, 1, 6

• High-dose UDCA (28-30 mg/kg/day) MUST BE AVOIDED due to increased mortality, serious adverse events, higher rates of liver transplantation, and development of varices. 7, 1, 6
• Low-dose UDCA (10-15 mg/kg/day) improves liver biochemistry but does not improve clinical outcomes including death, transplantation, or disease progression. 7, 1
• Moderate-dose UDCA (15-20 mg/kg/day) may be considered in highly selected cases as it can improve serum liver tests and surrogate markers of prognosis, though available data does not support a firm recommendation. 7, 1, 6
• One uncontrolled study showed worsening liver biochemistry and pruritus after stopping UDCA in patients already on treatment, but this does not justify routine initiation. 7

Gallstone Dissolution

For radiolucent gallbladder stones, use 8-10 mg/kg/day given in 2 or 3 divided doses. 2

• Ultrasound images should be obtained at 6-month intervals for the first year to monitor gallstone response. 2
• If partial stone dissolution is not seen by 12 months, the likelihood of success is greatly reduced. 2
• Success rates reach approximately 80% when stringent selection criteria are applied (non-calcified floating cholesterol stones <10-15 mm diameter). 8
• The optimal dose of 8-10 mg/kg/day achieves biliary ursodeoxycholic acid concentrations of 50-60% of total bile acids. 9

Gallstone Prevention During Rapid Weight Loss

For gallstone prevention in patients undergoing rapid weight loss, use 600 mg/day (300 mg twice daily). 2

Common Pitfalls and Caveats

• Never exceed 20 mg/kg/day in any cholestatic liver disease except for carefully selected gallstone dissolution cases, as higher doses have been linked to adverse outcomes, especially in PSC. 1, 6
• UDCA does not significantly improve fatigue or pruritus in PBC; use cholestyramine, rifampicin (300-600 mg daily), or other anion-exchange resins for pruritus management instead. 3, 6
• When UDCA is used concurrently with cholestyramine, administer the two agents at least 4 hours apart to avoid absorption interference. 6
• Diarrhea is a dose-related adverse effect occurring in up to 25% of patients, though it is generally mild. 3
• Verify medication adherence before attributing abnormal liver biochemistry to treatment failure, as non-adherence can produce sudden rises in liver tests. 6
• Regular monitoring of liver biochemistry is essential to assess treatment response across all indications. 1